Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyloidosis
Reports outline amyloidosis study findings from N. Ostovari and colleagues
May 18th, 2008
" Macular amyloidosis is a primary form of skin amyloidosis with deposition of small to moderate amyloid material in the upper dermis and mild pigmentary incontinence with resultant clinical hyperpigmentation. Objectives To determine the efficiency of Q-switched Nd:YAG laser (532 and 1064 nm) in reducing the pigmentations due to skin macular amyloidosis," scientists writing in the Journal of the European Academy of Dermatology and Venereology report. " A prospective, side by side, controlled, clinical trial study was designed. Twenty subjects with clinical diagnosis and pathology confirmation of macular amyloidosis were treated with Q-switched Nd:YAG laser: 532...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-18)
|
